^
Association details:
| Biomarker: | BRAF mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | belrestotug (EOS-448) (TIGIT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
CT118 - Preliminary data from Phase I first-in-human study of EOS884448, a novel potent anti-TIGIT antibody, monotherapy shows favorable tolerability profile and early signsof clinical activity in immune-resistant advanced cancers
Published date:
03/10/2021
Excerpt:
Twenty-two adult participants with advanced solid malignancies have been treated with EOS884448 monotherapy….Among the 20 patients who had at least one disease assessment, stable disease was observed in 8 participants, 4 of whom remain on therapy, and 1 partial response was observed in a patient with checkpoint inhibitor-refractory, BRAF-mutated melanoma.
Trial ID:
